Ginkgo Bioworks Logo
US37611X1000

Ginkgo Bioworks

Ins Portfolio
Über 2000 Dividenden-Werte in einem kostengünstigen ETF. Jetzt entdecken
Anzeige

Kurse werden geladen...

Prognose

Das durchschnittliche Kursziel der Analysten beträgt +6,40(0,62%). Der Median liegt bei +5,67(11,96%).

Kaufen
  5
Halten
  1
Verkaufen
  2

Scoring-Modelle

Dividenden-Strategie0 / 15
HGI-Strategie6 / 18
Levermann-Strategie-1 / 13
Powered byaktien.guide

News

  • Foto von Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

    Applied DNA's LineaRx Subsidiary Stands Ready to Support the Reshoring of Drug Development and Manufacturing with U.S.-Produced Synthetic DNA

    - Pivot to U.S.-based Supply Chain for Critical Input Materials Completed - STONY BROOK, NY / ACCESS Newswire / April 21, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA or the "Company"), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company's majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA™ and LineaIVT™ platforms from U.S.-based suppliers. The initiative, undertaken in response to the 2024 BIOSECURE Act and customer demand for a U.S.-based supply chain, comes as the biopharmaceutical industry increasingly considers reshoring manufacturing operations to the U.S. in response to potential tariff impacts and to ensure a stable supply chain.» Mehr auf accessnewswire.com

  • Foto von Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

    Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors

    STATEN ISLAND, N.Y. , April 17, 2025 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections, today announced that a new patent has been granted by the Indian Patent Office in March 2025.» Mehr auf prnewswire.com

  • Foto von Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

    Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain

    Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , April 10, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced a new contract with the Advanced Research Projects Agency for Health (ARPA-H), alongside partners Tritica Biosciences , US Pharmacopeia (USP), On Demand Pharmaceuticals , and Isolere Bio by Donaldson . This two-year program, Wheat-based High efficiency Enzyme and API Technology (WHEAT), aims to establish a new manufacturing process for the distributed production of biologic and small molecule active pharmaceutical ingredients (APIs) using wheat germ cell-free expression systems.» Mehr auf prnewswire.com

Unternehmenszahlen

Im letzten Quartal hatte Ginkgo Bioworks einen Umsatz von +42,14 Mio und ein Nettoeinkommen von 103,34 Mio
(EUR)Dez. 2024
YOY
Umsatz+42,14 Mio34,03%
Bruttoeinkommen+32,89 Mio93,33%
Nettoeinkommen103,34 Mio46,04%
EBITDA137,89 Mio43,36%

Fundamentaldaten

MetrikWert
Marktkapitalisierung
+371,52 Mio
Anzahl Aktien
58,03 Mio
52 Wochen-Hoch/Tief
+39,42 - +4,36
DividendenNein
Beta
1,35
KGV (PE Ratio)
0,70
KGWV (PEG Ratio)
0,04
KBV (PB Ratio)
+0,53
KUV (PS Ratio)
+1,88

Unternehmensprofil

Ginkgo Bioworks Holdings, Inc. entwickelt zusammen mit seinen Tochtergesellschaften eine Plattform für die Zellprogrammierung. Die Plattform wird zur Programmierung von Zellen verwendet, um die biologische Herstellung von Produkten wie neuartigen Therapeutika, Lebensmittelzutaten und aus Erdöl gewonnenen Chemikalien zu ermöglichen. Das Unternehmen bedient verschiedene Endmärkte, darunter Spezialchemikalien, Landwirtschaft, Lebensmittel, Konsumgüter und Pharmazeutika. Ginkgo Bioworks hat eine Partnerschaft mit Selecta Biosciences, Inc. zur Entwicklung der ImmTOR-Technologieplattform. Ginkgo Bioworks Holdings, Inc. wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in Boston, Massachusetts.

Name
Ginkgo Bioworks
CEO
Dr. Jason Kelly Ph.D.
SitzBoston, ma
USA
Website
Industrie
Biotechnologie
Börsengang
Mitarbeiter834

Ticker Symbole

BörseSymbol
NYSE
DNA
🍪

Parqet nutzt Cookies.Erfahre Mehr